Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-10-13

FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, indicating an approved change to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vyvanse (lisdexamfetamine dimesylate)

Snippet

SUPPL AP for VYVANSE (LISDEXAMFETAMINE DIMESYLATE)